CIK 0001783328
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
TScan Therapeutics, Inc.
Sign in to watch- Ticker
- TCRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 825282075
- Phone
- +1 857-399-9500
- Business address
- 830 WINTER STREET, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-08-23 | ZDRAVESKI ZORAN See Remarks | Option exercise | +64,166 | $2.49 | $160K | 169,402 |
| 2024-08-23 | ZDRAVESKI ZORAN See Remarks | Sale | −164,686 | $5.78 | $952K | 4,716 |
| 2024-08-23 | ZDRAVESKI ZORAN See Remarks | Option exercise · Stock Option (Right to Buy) | −54,895 | 30,105 | ||
| 2024-08-23 | ZDRAVESKI ZORAN See Remarks | Option exercise · Stock Option (Right to Buy) | −25,000 | 25,000 | ||
| 2024-08-23 | ZDRAVESKI ZORAN See Remarks | Option exercise · Stock Option (Right to Buy) | −13,125 | 21,875 | ||
| 2024-08-23 | ZDRAVESKI ZORAN See Remarks | Option exercise · Stock Option (Right to Buy) | −64,166 | 365,834 | ||
| 2024-06-12 | Woods Keith Director | Grant or award · Stock Option (Right to Buy) | +47,500 | 47,500 | ||
| 2024-06-12 | Dorton Katina Director | Grant or award · Stock Option (Right to Buy) | +47,500 | 47,500 | ||
| 2024-06-12 | Klencke Barbara Director | Grant or award · Stock Option (Right to Buy) | +47,500 | 47,500 | ||
| 2024-06-12 | Gruia Gabriela Director | Grant or award · Stock Option (Right to Buy) | +47,500 | 47,500 | ||
| 2024-06-12 | Nicholson Garry A Director | Grant or award · Stock Option (Right to Buy) | +47,500 | 47,500 | ||
| 2024-06-12 | Nicholson Garry A Director | Grant or award · Stock Option (Right to Buy) | +23,750 | 23,750 | ||
| 2024-06-12 | BAKER BROS. ADVISORS LP Director | Grant or award · Non- Qualified Stock Option (right to buy) | +47,500 | 47,500 | ||
| 2024-06-12 | BAKER BROS. ADVISORS LP Director | Grant or award · Non- Qualified Stock Option (right to buy) | +47,500 | 47,500 | ||
| 2024-05-01 | Louis Chrystal Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +380,000 | 380,000 | ||
| 2024-04-19 | BAKER BROS. ADVISORS LP Director | Purchase · Warrants to purchase Common Stock | +825,968 | $7.13 | $5.9M | 4,018,678 |
| 2024-04-19 | BAKER BROS. ADVISORS LP Director | Purchase · Warrants to purchase Common Stock | +8,851,451 | $7.13 | $63.1M | 43,158,741 |
| 2024-04-19 | Lynx1 Capital Management LP 10% owner | Purchase · Pre-funded Warrant (right to buy) | +5,000,000 | $7.13 | $35.6M | 5,000,000 |
| 2024-02-01 | Amello Jason Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +750,000 | 750,000 | ||
| 2024-01-12 | ZDRAVESKI ZORAN See Remarks | Grant or award · Stock Option (Right to Buy) | +52,500 | 52,500 |
Page 3 of 8 · 144 trades